A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 19, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Nov 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the EVH SEC filings page.
Evolent Health, Inc (EVH) reported $2.3B in revenue over the twelve months to Sep 30, 2026, up 14.1% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Gross profit recovered while operating losses and leverage worsened, making financing structure more consequential than topline growth.
Operating income was-$410.1M despite gross profit of$399.9M , so overheads or other operating charges outweighed the reported gross profit. The$38.8M operating cash flow versus a$534.5M net loss indicates earnings were heavily affected by noncash items or working-capital movements.
Gross margin reached
Debt-to-equity reached 2.3x from 0.5x in FY2024, showing a much thinner equity cushion. Total equity was
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed: here 5 of 6, with the others left out rather than counted as zero. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Evolent Health, Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Profitability ranks operating companies on their operating margin with gains on asset sales taken out, averaged over the last three fiscal years with the newest counting most, and in smaller part on how steady that margin has been. Evolent Health, Inc scores 20/100 on it among other operating companies.
Growth ranks operating companies on the yearly rate at which revenue compounded across the last three fiscal years (the last two where the earliest reports no revenue), counted in the currency each company reports in so that a move in the exchange rate is not read as growth. Evolent Health, Inc scores 23/100 on it among other operating companies.
Evolent Health, Inc carried $2.34 of long-term debt for every $1 of shareholders' equity at the end of fiscal year 2025, a debt-to-equity ratio of 2.34. With no positive EBITDA in fiscal year 2025, Evolent Health, Inc is ranked on that ratio rather than on net debt against EBITDA, a lower ratio being the safer one, and scores 15/100 among other operating companies measured the same way.
Evolent Health, Inc held $1.31 of current assets for every $1 of current liabilities at the end of fiscal year 2025, a current ratio of 1.31. Liquidity ranks operating companies on that ratio, and Evolent Health, Inc scores 35/100 among other operating companies.
Not available for Evolent Health, Inc, so it is left out of the overall score, which averages the 5 of 6 dimensions that can be computed.
Returns ranks operating companies on their return on capital employed, which is operating income against total assets less current liabilities, averaged over three fiscal years with the newest weighted most, and in smaller part on how steady that return has been. Evolent Health, Inc scores 17/100 on it among other operating companies.
Evolent Health, Inc scores -0.46, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $1.3B against total assets of $1.9B. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Evolent Health, Inc passes 5 of 9 financial strength tests. 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, 1 of 2 operating efficiency signals passes.
Evolent Health, Inc reported a net loss of $534.5M while generating $38.8M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
Evolent Health, Inc reported an operating loss of $410.1M against $57.5M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Evolent Health, Inc generated $725.4M in revenue in Q3 2026. This represents an increase of 51.3% from the same quarter a year earlier. Against the prior quarter it is up 11.2%.
Evolent Health, Inc's EBITDA was $15.3M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 37.5% from the same quarter a year earlier. Against the prior quarter it is up 27.5%.
Evolent Health, Inc reported a net loss of $23.6M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Evolent Health, Inc earned -$0.21 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Cash & Balance Sheet
Evolent Health, Inc held $148.3M in cash against $969.5M in long-term debt as of Q3 2026.
Not reported for Q3 2026.
Not reported for Q3 2026.
Margins & Returns
Evolent Health, Inc's gross margin was 12.2% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is down 8.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.2 percentage points.
Evolent Health, Inc's operating margin was -0.9% in Q3 2026, reflecting core business profitability. This is down 1.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.6 percentage points.
Evolent Health, Inc's net profit margin was -3.3% in Q3 2026, showing the share of revenue converted to profit. This is up 1.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.1 percentage points.
Evolent Health, Inc's quarterly ROE was -6.3% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is down 3.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.1 percentage points.
Capital Allocation
None of these metrics is reported for Q3 2026.
EVH Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | $725.4M+51.3% | $652.5M+46.9% | $496.2M+2.6% | $468.7M-27.5% | $479.5M-22.8% | $444.3M-31.3% | $483.6M-24.4% | $646.5M+16.3% |
| Cost of Revenue | $636.9M+67.7% | $571.7M+66.2% | $412.5M+8.2% | N/A | $379.8M-29.8% | $343.9M-36.3% | $381.2M-28.8% | N/A |
| Gross Profit | $88.4M-11.4% | $80.8M-19.5% | $83.8M-18.2% | N/A | $99.8M+23.6% | $100.4M-6.0% | $102.5M-1.6% | N/A |
| SG&A Expenses | $73.1M-5.8% | $68.8M-8.5% | $72.8M-7.1% | N/A | $77.6M+15.7% | $75.2M+8.7% | $78.4M-0.9% | N/A |
| Operating Income | -$6.2M-798.4% | -$9.6Mn/m | -$10.6Mn/m | N/A | $886Kn/m | -$1.2M-115.0% | -$1.6Mn/m | N/A |
| EBITDA | $15.3M-37.5% | $12.0M-45.4% | $11.0M-51.2% | N/A | $24.5M+82.4% | $22.0M-41.7% | $22.4M+39.4% | N/A |
| Interest Expense | $17.0M+3.2% | $16.9M+45.3% | $16.9M+62.4% | N/A | $16.5M+174.1% | $11.6M+93.5% | $10.4M+73.2% | N/A |
| Income Tax | $1.1M+23.4% | $2.7Mn/m | $910K-38.1% | N/A | $906Kn/m | -$825Kn/m | $1.5M+160.2% | N/A |
| Net Income | -$23.6Mn/m | -$28.4Mn/m | -$26.6Mn/m | -$429.1Mn/m | -$20.9Mn/m | -$19.9M-1346.7% | -$64.6Mn/m | -$22.8Mn/m |
| EPS (Basic) | -$0.21n/m | -$0.25n/m | -$0.24n/m | -$3.84n/m | -$0.24n/m | -$0.44n/m | -$0.63n/m | -$0.27n/m |
| EPS (Diluted) | -$0.21n/m | -$0.25n/m | -$0.24n/m | -$3.84n/m | -$0.24n/m | -$0.44n/m | -$0.63n/m | -$0.27n/m |
| Diluted Shares (Avg) | 113M-0.9% | 113M-2.9% | 112M-3.0% | N/A | 114M-0.7% | 116M+1.0% | 115M+1.0% | N/A |
Not reported in any period shown, so not listed: R&D Expenses.
EVH Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'25Filing | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $2.0B-20.0% | $2.0B-19.9% | $1.9B-29.2% | $1.9B-25.4% | $2.5B-1.9% | $2.5B-0.5% | $2.7B+0.4% | $2.5B-5.1% |
| Current Assets | $617.1M+8.2% | $610.5M+8.6% | $502.0M-31.0% | $506.4M-16.6% | $570.1M+4.8% | $562.3M+7.9% | $727.9M+8.8% | $607.1M-11.2% |
| Cash & Equivalents | $148.3M+27.1% | $115.7M-23.4% | $142.0M-42.4% | $151.9M+45.7% | $116.7M+20.8% | $151.0M+49.1% | $246.5M+49.3% | $104.2M-46.0% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Accounts Receivable | $442.8M+14.5% | $449.1M+25.2% | $314.2M-27.0% | $309.9M-25.3% | $386.6M-5.2% | $358.8M-4.0% | $430.5M+0.6% | $414.7M-7.2% |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Goodwill | $694.4M-35.4% | $694.4M-38.9% | $694.4M-38.9% | $694.5M-38.9% | $1.1B-5.4% | $1.1B+1.9% | $1.1B+1.9% | $1.1B+1.9% |
| Total Liabilities | $1.6B-1.4% | $1.6B+18.8% | $1.5B-2.8% | $1.5B+9.7% | $1.6B+26.3% | $1.3B+8.1% | $1.5B+7.8% | $1.4B-5.7% |
| Current Liabilities | $489.9M+14.0% | $492.8M-11.6% | $381.2M-48.4% | $385.3M-46.2% | $429.9M-17.9% | $557.5M+15.3% | $739.1M+12.2% | $715.5M+6.1% |
| Non-Current Liabilities | $1.1B-6.9% | $1.1B+40.6% | $1.1B+40.2% | $1.1B+72.4% | $1.2B+57.0% | $779.2M+3.4% | $785.6M+4.0% | $637.5M-16.1% |
| Long-Term Debt | $969.5M-8.1% | $966.5M+49.0% | $973.5M+50.3% | $970.5M+97.9% | $1.1B+75.9% | $648.5M+8.3% | $647.5M+8.3% | $490.5M-17.8% |
| Total Equity | $372.9M-55.7% | $383.2M-57.2% | $396.4M-57.6% | $415.2M-58.5% | $842.2M-18.9% | $896.0M-15.0% | $935.5M-10.7% | $1.0B-6.2% |
| Retained Earnings | -$1.4Bn/m | -$1.4Bn/m | -$1.3Bn/m | -$1.3Bn/m | -$886.2Mn/m | -$865.3Mn/m | -$845.4Mn/m | -$780.8Mn/m |
Not reported in any period shown, so not listed: Inventory.
EVH Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $26.4M+66.8% | -$9.3Mn/m | -$984K-121.6% | $48.8Mn/m | $15.8M-15.3% | -$30.3M-241.6% | $4.6M-7.0% | -$26.2M-129.3% |
| Depreciation & Amortization | $21.5M-9.0% | $21.6M-6.8% | $21.6M-10.4% | $45.0M+53.7% | $23.6M-20.5% | $23.1M-22.5% | $24.1M-18.5% | $29.3M-1.0% |
| Stock-Based Compensation | $14.8M+0.8% | $15.2M+31.3% | $10.6M-3.9% | N/A | $14.7M+1.8% | $11.6M-8.5% | $11.1M-41.0% | N/A |
| Investing Cash Flow | -$7.1Mn/m | -$6.7Mn/m | -$6.4Mn/m | $82.2Mn/m | -$8.8Mn/m | -$60.5Mn/m | -$13.1Mn/m | -$19.9Mn/m |
| Financing Cash Flow | -$4.6Mn/m | -$11.0Mn/m | -$4.0M-103.7% | -$93.0M-196.0% | -$41.8Mn/m | -$8.9Mn/m | $107.9M+624.7% | $96.9Mn/m |
| Share Buybacks | N/A | N/A | N/A | $0n/m | N/A | N/A | N/A | $0 |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid.
EVH Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 12.2%-8.6pp | 12.4%-10.2pp | 16.9%-4.3pp | N/A | 20.8%+7.8pp | 22.6%+6.1pp | 21.2%+4.9pp | N/A |
| Operating Margin | -0.9%-1.0pp | -1.5%-1.2pp | -2.1%-1.8pp | N/A | 0.2%+2.8pp | -0.3%-1.5pp | -0.3%+1.8pp | N/A |
| Net Margin | -3.3%+1.1pp | -4.3%+0.1pp | -5.4%+8.0pp | -91.5%-88.0pp | -4.3%-0.6pp | -4.5%-4.7pp | -13.4%-10.7pp | -3.5%+2.5pp |
| Return on Equity | -6.3%-3.8pp | -7.4%-5.2pp | -6.7%+0.2pp | -103.4%-101.1pp | -2.5%-0.2pp | -2.2%-2.4pp | -6.9%-5.3pp | -2.3%+0.9pp |
| Return on Assets | -1.2%-0.3pp | -1.4%-0.6pp | -1.4%+1.0pp | -22.6%-21.7pp | -0.9%+0.1pp | -0.8%-0.9pp | -2.4%-1.8pp | -0.9%+0.4pp |
| Current Ratio | 1.26-0.1x | 1.24+0.2x | 1.32+0.3x | 1.31+0.5x | 1.33+0.3x | 1.01-0.1x | 0.980.0x | 0.85-0.2x |
| Debt-to-Equity | 2.60+1.3x | 2.52+1.8x | 2.46+1.8x | 2.34+1.8x | 1.25+0.7x | 0.72+0.2x | 0.69+0.1x | 0.49-0.1x |
| Liabilities-to-Equity | 4.26+2.3x | 4.15+2.7x | 3.74+2.1x | 3.57+2.2x | 1.91+0.7x | 1.49+0.3x | 1.63+0.3x | 1.350.0x |
| Asset Turnover | 0.37+0.2x | 0.33+0.2x | 0.26+0.1x | 0.250.0x | 0.20-0.1x | 0.18-0.1x | 0.18-0.1x | 0.250.0x |
Not reported in any period shown, so not listed: FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Evolent Health, Inc EVH | FY2025 | $1.9B | -$534.5M | -28.5% | $388.0M | 22/100 |
| NRC Health NRC | FY2025 | $137.4M | $11.3M | 8.2% | $530.3M | 51/100 |
| Claritev Corporation CTEV | FY2025 | $965.4M | -$284.3M | -29.4% | $324.9M | 18/100 |
| Carlsmed, Inc. CARL | FY2025 | $50.5M | -$29.6M | -58.7% | $471.9M | 54/100 |
| SOPHiA GENETICS SA SOPH | FY2025 | $77.3M | -$79.0M | N/A | $639.9M | 63/100 |
| Phreesia, Inc. PHR | FY2026 | $480.6M | $2.3M | 0.5% | $736.8M | 47/100 |
Where Evolent Health, Inc Ranks
Frequently Asked Questions
Evolent Health, Inc (EVH) reported $1.9B in total revenue for fiscal year 2025. This represents a -26.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Evolent Health, Inc (EVH) revenue declined by 26.6% year-over-year, from $2.6B to $1.9B in fiscal year 2025.
No, Evolent Health, Inc (EVH) reported a net loss of $507.7M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $534.5M, with a net profit margin of -28.5%.
Evolent Health, Inc (EVH) had EBITDA of -$294.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
As of fiscal year 2025, Evolent Health, Inc (EVH) had $151.9M in cash and equivalents against $970.5M in long-term debt.
Evolent Health, Inc (EVH) had a gross margin of 21.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
Evolent Health, Inc (EVH) had an operating margin of -21.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
Evolent Health, Inc (EVH) had a net profit margin of -28.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
Evolent Health, Inc (EVH) has a return on equity of -128.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
Evolent Health, Inc (EVH) generated $38.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
Evolent Health, Inc (EVH) had $1.9B in total assets as of fiscal year 2025, including both current and long-term assets.
Evolent Health, Inc (EVH) had a current ratio of 1.31 as of fiscal year 2025, which is considered adequate.
Evolent Health, Inc (EVH) had a debt-to-equity ratio of 2.34 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
Evolent Health, Inc (EVH) had a liabilities-to-equity ratio of 3.57 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
Evolent Health, Inc (EVH) had a return on assets of -28.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Evolent Health, Inc (EVH) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $388.0M as of Nov 19, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Evolent Health, Inc (EVH) trades at 0.2x sales, its market capitalization divided by $2.3B revenue, trailing 12 months to September 30, 2026. The market capitalization is $388.0M as of Nov 19, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Evolent Health, Inc (EVH) has an Altman Z-Score of -0.46, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
Evolent Health, Inc (EVH) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Evolent Health, Inc (EVH) reported a net loss of $534.5M while generating $38.8M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Evolent Health, Inc (EVH) reported an operating loss of $410.1M against $57.5M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
Evolent Health, Inc (EVH) scores 22 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. For Evolent Health, Inc it averages the 5 of 6 dimensions that can be computed; the others are left out rather than counted as zero. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.